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Summary 
  
  
Background and purpose. Partial agonists selective for α4β2 nicotinic 
acetylcholine receptors have been developed for smoking cessation as they 
induce weak activation of native α4β2* receptors and inhibit effect of nicotine. 
However, it is unclear whether at brain functions there is an existence of receptor 
reserve that allows weak receptor activation to induce maximum physiological 
effects. We assessed the extent of α4β2 partial agonist-induced increase of firing 
rate in dopaminergic neurons and evaluated the influence of receptor reserve.  
Experimental approach. The relative maximal effects and potencies of six 
nicotinic agonists were assessed on recombinant human α4β2 and α7 receptors 
expressed in mammalian cell lines by measuring calcium influx. Agonist-induced 
increase of the spontaneous firing rate of dopaminergic neurons was recorded 
using microelectrodes in the ventral tegmental area of rat brain slices.   
Key Results. All α4β2 partial and full agonists increased the firing rate 
concentration-dependently. Their sensitivity to subtype-selective antagonists 
showed predominant activation of native α4β2* receptors. However, partial 
agonists with relative maximal effects as low as 33% on α4β2 receptors 
maximally increased the firing rate and induced additional depolarisation block of 
firing, demonstrating that partial activation of receptors caused the maximum 
increase in firing rate in the presence of a receptor reserve. 
Conclusions and implications. Partial α4β2 agonists induced relatively 
enhanced effects on the firing rate of dopaminergic neurons, and the effect was 
mainly attributed to the existence of native α4β2* receptor reserve. The results 
have implications in the understanding of physiological effects and therapeutic 
efficacies of α4β2 partial agonists. 
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Introduction   
The α4β2* nAChRs are the primary drug target for treating nicotine addiction, 
possibly because they directly mediate nicotine-induced increase in firing rate in 
dopamine neurons of the ventral tegmental area (VTA) (Picciotto et al., 1998; 
Chen et al., 2003; Mameli-Engvall et al., 2006) leading to dopamine release and 
nicotine addiction (Picciotto et al., 1998; Marubio et al., 2003; Maskos et al., 
2005). Partial agonists for the α4β2 receptors show clinically efficacy for smoking 
cessation, presumably via the dual mechanisms of partial receptor activation and 
competitive antagonism against nicotine (Coe et al., 2005). While the former 
maintains a low level of nicotinic activity to prevent withdrawal symptoms during 
abstinence, the latter blocks effects of nicotine from smoking via receptor 
occupation. Cytisine, a high-affinity α4β2 receptor partial agonist, has been used 
in Eastern Europe for many years to treat tobacco dependence (Etter, 2006). 
Recently, varenicline (Coe et al., 2005), a cytisine derivative, has demonstrated 
even better clinical efficacy in maintaining abstinence in ex-smokers (Fagerstrom 
& Balfour, 2006; Cahill et al., 2011). However, to what extent the therapeutic 
delivery of α4β2 partial agonists elicit physiological effects remain controversial.  
Chronic administration of partial agonists may predominantly 
desensitise native α4β2* receptors in the brain (Picciotto et al., 2008), as bath 
applications of agonists cause long-term decrease of response to agonists 
(Papke & Heinemann, 1994; Quick & Lester, 2002). Receptor activation is, 
however, transient and dependent on agonist concentration and the speed of 
agonist application. Prolonged application of α4β2 partial agonists may, therefore, 
only persistently activate receptors over a narrow “window” of concentrations 
where balance between activation and desensitisation is achieved (Lester, 2004; 
Rollema et al., 2010; Papke et al., 2011). 
However, bath applications of nicotine induce α4β2* receptor 
activation on dopamine neurons, and persistent increase in firing rate (Picciotto 
et al., 1998; Yin & French, 2000; Chen et al., 2003; de Filippi et al., 2010), 
showing steady-state α4β2* receptor activation of the reward pathway of the 
brain. We also found that TC-2559, a 33% α4β2 partial agonist (relative to 
epibatidine and ~50% relative to nicotine), stimulated dopamine neuron firing via 
prolonged bath application in VTA slices in a DHβE-sensitive manner (Chen et 
al., 2003). The effect was also mimicked by systemic administration in vivo 
(Wang et al., 2006), showing that α4β2 partial agonists also persistently stimulate 
native α4β2* receptors on dopamine neurons.  
TC-2559 also induced similar effects to nicotine on dopamine neuron 
firing (Chen et al., 2003; Wang et al., 2006), neurotransmitter release and several 
cognitive performances (Bencherif et al., 2000), indicating its potential to elicit 
relatively enhanced effects on native functions. However, quantitative 
pharmacological studies have shown that it is less effective than nicotine at 
inducing dopamine release (Smith et al., 2007). TC-2559 may, therefore, still be 
a partial agonist on native rodent α4β2* receptors.  
In the case where a partial agonist induced relatively enhanced effect, 
a receptor reserve may be present (Stephenson, 1956; Furchgott & Bursztyn, 
1967). Receptor reserve describes a situation where a full receptor agonist may 
produce the maximal effect by recruiting only part of the receptor pool, leaving 
the rest of the receptors in “reserve”. In such case, a partial agonist may still 
weakly activate receptors but elicit the maximum effect by recruiting all receptors 
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available. Partial and full agonists may thus achieve the same maximum 
physiological effects by recruiting different proportions of the receptor pool.  
However, full agonists can further activate the receptors in reserve at 
high concentrations and induce additional effects. As the activation of nicotinic 
receptors depolarises membrane potential and increases firing rate in dopamine 
neurons (Calabresi et al., 1989), excessive receptor stimulation could depolarise 
to a level beyond the firing threshold and cause inactivation of Na+ channels and 
failure to generate action potential, cumulating in depolarisation block of firing 
(Grace & Bunney, 1984). Agonist-induced depolarisation block may, then, 
indicate the existence of receptor reserve.  
 We systematically examined the relative maximal effects of six α4β2 
agonists on recombinant α4β2 receptors and dopamine neuron firing rate 
increase. Results show relatively enhanced effects of partial agonists on 
dopamine neuron firing and suggest an existence of nicotinic receptor reserve.  
 
Materials and Methods  
Calcium influx in mammalian cell lines expressing nAChRs 
 
Human α4β2 nAChRs were stably expressed in HEK293 cells that were cultured 
in DMEM supplemented with 10% foetal calf serum, 100 units/ml penicillin, 100 
µg/ml streptomycin, 4 mM glutamine and 50 µg/ml geneticin. GH4 cells that 
express endogenous Ric-3 were used to express α7 nAChRs (Lansdell et al., 
2005; Williams et al., 2005), and they were cultured in F-10 nutrient mixture with 
the same supplements used for HEK293 cells. The use of receptor nomenclature 
conforms to (Alexander et al., 2009). 
Agonist-induced calcium dynamics through open channels 
(Kuntzweiler et al., 1998; Fucile et al., 2005) was measured using a FLIPR 
(Fluorescent Imaging Plate Reader, Molecular Devices, Winnersh, UK) (Chen et 
al., 2003; Broad et al., 2006). Cell lines were plated overnight in black-walled, 
transparent bottomed 96-well plates (Poly-D-lysine coated, Marathon 
Laboratories), at a density of 0.5x106 cells/ml for HEK293 cells, and 1.0x106 
cells/ml for GH4 cells. All cells were grown in a humidified incubator maintained 
with 5% CO2 in air at 37°C. Note that changes in incubation temperature may 
alter the subunit composition of α4β2 receptors and their sensitivity to ACh 
(Zwart et al., 2006). Cells were loaded with Fluo-3-AM (10 µM in Hepes-buffered 
saline solution) for 1 hour at room temperature before the dye was removed. The 
plates were then transferred to the FLIPR system for measurements.  
Fluorescence emission was recorded every second for the first minute 
following agonist addition, with subsequent readings every 6 seconds for a 
further 2 minutes. Responses were measured as peak minus basal fluorescence 
intensity and expressed as percentage of the maximum response induced by 1 
µM epibatidine in each experiment. Concentration-response relationships were 
obtained for each agonist with data from separate experiments and the EC50 and 
Emax values on α4β2, α3β4 and α7 nAChRs were calculated using the Hill 
equation. Note that the Emax values represent the relative maximal responses of 
agonists on each receptor subtype, which may not be the absolute value of 
efficacy, the measure of the maximum probability of ion channels being open at 
high concentrations of agonist (Colquhoun, 1998). 
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Recording of neuronal firing in brain slices 
 
Coronal midbrain slices (350 µm) containing the VTA were prepared from male 
Sprague-Dawley rats (25 - 40 days old) following procedures in compliance with 
the UK Animal (Scientific Procedure) Act 1986. Sections were cut using a 
Campden vibroslicer in ice-cold, oxygenated, artificial cerebrospinal fluid (aCSF), 
which contained (in mM) NaCl 123, NaHCO3 22, NaH2PO4 1.25, KCl 3.75, D-
Glucose 10, CaCl2 2.5 and MgSO4 1.2. The VTA was visually identified as a grey 
area medial to the substantial nigra and the medial lemniscus, a white fibre tract.  
Single cell extracellular recordings were made using glass 
microelectrodes filled with aCSF (impedance of 3-6 MΩ) (Yin & French, 2000; 
Chen et al., 2003; de Filippi et al., 2010). Under constant superfusion with 
oxygenated ACSF at a flow rate of ~3 ml/min at 34oC, the spontaneous neuronal 
firing can be recorded for more than 6 hours, which allow for the examination of 
prolonged applications of agonists at different concentrations. Yet, the frequency 
of spikes and the duration of the extracellular action potential waveform were 
similar to those recorded in vivo (Wang et al., 2006). Recording from single 
neurons was selected where spikes amplitude and duration were uniform. 
Signals were captured using Axopatch 1D in I = 0 mode with a low cut-off 
frequency of 2 kHz and then further amplified by 100 times in the AC mode using 
a Neurolog system (Digidata, Cambridge, UK) without any further filtering. 
Signals were then digitised using CED1401 plus (CED, Cambridge, UK) and 
captured using Spike 2 software (CED, Cambridge, UK).  
 Two types of spontaneously firing neurons in the VTA were recorded 
and identified. The majority was the classically-defined dopamine neurons, which 
displayed spontaneous single-spike firing pattern at a rate between 0.5 and 4 Hz 
with action potential waveforms of 2.5 – 3 ms in duration, including a large 
negative phase (Grace & Onn, 1989; Johnson & North, 1992). The firing 
frequency of these neurons was significantly suppressed by 50 µM dopamine (-
74.2 ± 4.8%, n = 29) (Yin & French, 2000; Chen et al., 2003). The other type was 
known as the non-dopaminergic or GABAergic neurons (Grace & Onn, 1989; 
Johnson & North, 1992), which displayed higher firing frequency (4 – 15 Hz), 
regular firing pattern, and an action potential waveform of a shorter duration (~ 
2ms). Dopamine did not inhibit the firing of these neurons (N = 18). A recent 
study confirmed that almost all dopaminergic neurons classified by their 
electrophysiological characteristics are tyrosine hydroxylase-positive (Brown et 
al., 2009), despite discrepancies found in other studies (Margolis et al., 2006; 
Lammel et al., 2008). Dopamine neurons referred to in this study conform to the 
electrophysiological and pharmacological criteria, but not necessarily the content 
of dopamine. 
The baseline firing frequency of a neuron was established from a 
recording period of more than 4 min. Receptor agonists and antagonists were 
dissolved in aCSF and delivered to the slice via a switch from control aCSF. 
Agonists were applied for a minimum of 4 min to ensure that equilibrium was 
reached. The peak frequency was calculated using the mean of three 
consecutive 10s bins containing 15 - 120 spikes. Sufficient wash-out period (> 20 
min) was given between consecutive agonist applications and was verified by 
obtaining repeatable responses (de Filippi et al., 2010). However, multiple 
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applications of agonists to a single slice were only performed to illustrate 
concentration-dependent effects or to compare effects of two agonists on the 
same neuron. 
 
Pharmacological agents 
Dopamine hydrochloride, (-)-nicotine hydrogen tartrate (nicotine), cytisine and 
dihydro-β-erythroidine hydrobromide (DHβE) were obtained from Sigma-RBI 
(Poole, UK).  TC-2559 (5-ethoxy-metanicotine) and ABT-594 [(R)-5-(2-
azetidinylmethoxy)-2-chloropyridine] were synthesised at Lilly Chemistry 
Synthesis Laboratory (UK). (±)-Epibatidine hydrochloride, 5-I-A85380 (3-[(2s)-2-
azetidinylmethoxy]-5-iodopyridine), MLA (methyllycaconitine), α-conotoxin MII, 
CNQX and D-AP5 were purchased from Tocris (Avonmouth, UK). 
 
Statistics 
Numerical data in the text and figures are expressed as the mean ± standard 
error of the mean (S.E.M). ANOVA with appropriate posthoc tests, and Student’s 
t-test, unpaired or paired when appropriate, were used for statistical comparisons. 
 
Results: 
Relative maximal effects of nicotinic agonists on recombinant α4β2 
receptors  
Functional nicotinic receptors on dopamine neurons include both α4β2* (* may 
denote α5, α6 or both) and α7 subtypes (Pidoplichko et al., 1997; Picciotto et al., 
1998; Klink et al., 2001; Champtiaux et al., 2003). Here, we examined the 
pharmacological profiles of six nicotinic agonists on recombinant human α4β2 
and α7 receptors that are expressed in mammalian cell lines by measuring 
calcium influx (Chen et al., 2003). The EC50 and normalised Emax values for each 
agonist were obtained from concentration-response relationships (Table 1). 
Agonists displayed a range of EC50 values on α4β2 receptors, showing their 
different potencies. EC50 for cytisine could not be reliably calculated (N.D. Table 
1) due to the low amplitude of the response. Indeed, cytisine displayed the lowest 
Emax value of 21%, relative to epibatidine. Cytisine and TC-2559 (33%) are, 
therefore, partial α4β2 agonists, nicotine (75%) and 5-i-A85380 (73%, sum of 
both high and low-affinity components) more efficacious partial agonists, and 
epibatidine (100%) and ABT-594 (102%) are full agonists in this assay. The two 
components in the concentration-response curve for 5-i-A85380 may reflect its 
different potencies on the alternative stoichiometries of α4β2 receptors 
assembled with different α4 and β2 subunit ratios (Zwart et al., 2006).  
 On α7 nAChRs, TC-2559 and 5-I-A85380 had no detectable activity at 
concentrations as high as 100 µM, showing their selectivity for α4β2 receptors. 
ABT-594 was also more than 20 fold more potent on α4β2 receptors. Nicotine, 
cytisine and epibatidine are α4β2 agonists, but also have significant activity on 
α7 receptors. We have, therefore, identified six α4β2 agonists with different 
relative maximal effects on recombinant human receptors, and TC-2559, 5-I-
A85380 and ABT-594 are α4β2-selective.  
  
Concentration-dependent effects of α4β2 agonists on spontaneous firing 
rate of dopamine neurons 
We have previously shown that the α4β2 partial agonist TC-2559 increases the 
firing rate of dopamine neurons concentration-dependently in a DHβE-sensitive 
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manner (Chen et al., 2003). Here, we compared its relative maximal effects on 
neuronal firing with the other agonists by examining the concentration-dependent 
effects (n = 234 neurons, Fig. 1A and B). Nicotine induced effects are shown as 
an example (Fig. 1A). The concentration-dependent effects for each agonist 
spanned across concentration range of more than two orders of magnitude. 
Nicotine and other efficacious agonists, epibatidine, ABT-594, 5-I-A85380, also 
caused additional firing cessation (#) following the peak increase in firing rate (*) 
at high concentrations. The concentration-response relationships were fitted with 
the Hill equation (Fig. 1B). 
  α4β2-selective agonists TC-2559, 5-I-A85380 and ABT-594 showed 
similar Emax values on neuronal firing (Table 1), despite their different Emax values 
on recombinant α4β2 receptors. However, 5-I-A85380 and ABT-594 are more 
potent than TC-2559 on neuronal firing, which is in agreement with their 
respective EC50 values on recombinant α4β2 receptors. The partial agonist TC-
2559 is, therefore, relatively more effective on dopamine neuron firing. The Emax 
values of nicotine and epibatidine were also not different from TC-2559 (Table 1 
and Fig. 1B), indicating, again, its relatively enhanced effect on neuronal firing. 
Cytisine, however, induced a submaximal effect, of about 46% of epibatidine, 
which was enhanced from its 21% activity on recombinant α4β2 receptors. In 
addition, the maximal absolute increases in firing rate by TC-2559 and cytisine 
were also relatively larger (Fig. 1C). 
 Plotting the Emax values of agonists on neuronal firing against those on 
recombinant α4β2 nAChRs, hence, found most data points located above the 
diagonal line (dashed, Fig. 1D), showing relatively enhanced effects of partial 
agonists on neuronal firing. In addition, TC-2559, nicotine, epibatidine, ABT-594 
and 5-i-A85380 show similar Emax values, with the mean (91.6 ± 3.7%) shown as 
the dotted line (Fig. 1D), illustrating the similar maximal effects of partial agonists 
TC-2559, nicotine and 5-I-A85380 to full agonists epibatidine and ABT-594 on 
neuronal firing.  
 A linear correlation was, however, found between the EC50 values on 
neuronal firing and recombinant α4β2 receptors (Fig. 1E, r = 0.79 and slope = 1, 
the EC50 for 5-I-A85380 was taken from the higher affinity component on 
recombinant α4β2 nAChRs), indicating that agonists stimulate firing rate increase 
and recombinant α4β2 receptors with similar potencies.  
 
Native α4β2* receptors and firing rate increase in dopamine neurons 
Firing rate increase induced by α4β2-selective agonist TC-2559 was shown to be 
mediated by (non-α6/α7)α4β2* receptors previously (Chen et al., 2003). Here, we 
examined receptor subtypes mediating the effects of non-selective α4β2 agonists 
(Fig. 2A). Cytisine (Cyt, 10 µM, upper panel), nicotine (0.3 µM, middle panel), 
and epibatidine (Epi, 0.1 µM, lower panel) all caused steady-state increase in 
firing rate. Nicotinic antagonists mecamylamine (Mec, 10 µM) and DHβE (2 µM) 
inhibited the effects, confirming the activation of nicotinic receptors. The α3/6-
selective antagonist α-conotoxin MII (CTX MII, 100 nM) and the α7-selective 
antagonist methyllycaconitine (MLA, 10 nM) (Fig. 2B) did not cause significant 
inhibition. This suggests the predominant activation of native α4β2* receptors, 
with lack of effects by α3/6* or α7* receptors. 
 Co-application of ionotropic glutamate receptor antagonists CNQX (20 
µM) and D-AP5 (50 µM) did not significantly affect agonist-induced firing increase 
(Fig. 2B), showing a lack of contribution from glutamate release. α4β2* receptors 
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that are located extrasynaptically on somatodendritic sites of dopamine neurons 
(Lendvai & Vizi, 2008), may thus play a predominant role. 
 
Agonist-induced depolarisation block of firing  
The relatively enhanced effects of partial agonists could result from increased 
relative effects on native α4β2* nAChRs. However, a presence of receptor 
reserve may also enhance the effects of partial agonists. In the latter case, full 
agonist may induce an additional effect at high concentration when receptors in 
reserve are activated.  
 The maximal effects of cytisine and TC-2559 were characterised by 
persistent increase in firing rate (Fig. 2A upper panel and Chen et al. (2003)), but 
the maximal effect of nicotine (10 µM) showed an abrupt firing cessation (# in Fig. 
1A) after the initial firing rate increase (* in Fig. 1A). Furthermore, epibatidine (1 
µM, n = 14, Fig. 3A and B) and ABT-594 (1 µM, n = 7, data not shown) triggered 
firing blockade following the maximal increase in all neurons.  
 The firing blockade resembles depolarisation block due to excessive 
receptor activation and membrane depolarisation. The reduced spike amplitude 
seen during firing increase confirms the underlying membrane depolarisation (Fig. 
3A inset, spike waveform 2). Washing-out of epibatidine rapidly relieved firing 
blockade and the decreased spike amplitude (Fig. 3A and the overlapping 
waveforms 1 and 3 in the inset), and the residual firing rate increase was 
inhibited by DHβE (2 µM, n = 5, Fig. 3A), showing receptor activation.  
 The depolarisation block of firing by efficacious agonists may indicate 
their ability to further activate receptors at high concentrations. Plotting agonist-
induced incidence of firing blockade (% neurons) against the Emax values of 
agonists on recombinant α4β2 receptors revealed a linear correlation (P < 0.05, r 
= 0.99, slope = 1.1, Fig. 3C), showing that the more effective agonists on α4β2 
receptors are more likely to induce depolarisation blockade, presumably by 
further activation of α4β2* receptors that were surplus for the maximum firing 
increase, i.e. the “receptor reserve”. Conversely, partial α4β2 agonists, cytisine 
and TC-2559, showed much lowered incidence of depolarisation block, indicating 
that they activated all receptors to induce the maximal increase without any 
reserve. Note that receptor desensitisation may cause rapid decrease of effects 
similar to receptor antagonism, but not complete cessation of neuronal firing.  
 Furthermore, for the receptor reserve hypothesis to be true, all 
agonists must activate the same pool of receptors. Indeed, both firing increase 
and cessation induced by 1 µM epibatidine were fully blocked by the pre-
application of 10 µM TC-2559 (Fig. 4A, B). Partial and full agonists may thus 
activate the same population of α4β2* receptors for both firing increase and 
depolarisation block of firing.  
 As α4β2* nAChRs are also expressed on GABAergic neurons in the 
VTA (Klink et al., 2001; Mansvelder et al., 2002), agonists may stimulate 
GABAergic neurons and cause feed-forward inhibition of dopamine neuron firing. 
Epibatidine (1 µM), however, did not affect firing rate (11.4 ± 12.1% increase, 
basal frequency = 5.9 ± 2.0 Hz, n = 3, p > 0.05, Fig. 5A), or spike amplitude (Fig. 
5A inset, waveform 1 and 2) of GABAergic neurons. Comparing the effects of 1 
µM epibatidine, 1 and 100 µM TC-2559, on firing rate of GABAergic neurons (Fig. 
5B bar plot) with dopamine neurons (Fig. 5B scatter plot) showed significantly 
reduced effects (** P<0.01, one-way ANOVA with Dunn’s pair-wise comparisons), 
in agreement with the previously reported low sensitivity of GABAergic neurons 
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to nicotine (Yin & French, 2000). A small receptor pool on GABAergic neurons 
could contribute to the lower sensitivity to agonists. 
 
Effects of partial agonist and size of receptor pool 
The presence of a large receptor pool is likely to be essential for the existence of 
receptor reserve and for partial agonists to exert relatively enhanced effects. We 
further evaluated the relative size of the receptor pool between dopamine 
neurons. As the relative maximal effects of cytisine were induced presumably by 
activating all receptors, they may indicate the relative sizes of the receptor pool in 
individual dopamine neurons. The effects ranged between 13 and 89% of firing 
rate increase (n = 10 dopamine neurons), with a coefficient of variance (CV) of 
61%, demonstrating considerable variability between the size of the receptor pool.   
 In dopamine neurons with a larger receptor pool, partial agonists may 
exert relatively larger effects. When TC-2559 (1 µM, an EC50 concentration) was 
examined in the same neuron as cytisine (10 µM) (Fig. 6A), the effects were 
correlated (r = 0.90, slope = 1, ** p < 0.01, n = 10, Fig. 6B), indicating that TC-
2559 was more potent in neurons that express larger pool of receptors. In these 
experiments, TC-2559 was applied before cytisine (Fig. 6C), because its effect 
was rapidly washed out and repeatable in consecutive applications (Fig. 6C and 
D). Receptor availability may, therefore, modulate the effects of partial agonists.  
 
Antagonist effects of partial agonists   
Partial agonists are also thought to be effective antagonists against nicotine due 
to their potential to occupy a large proportion of the receptor pool. The presence 
of 10 µM TC-2559 was shown in Fig. 4A was indeed shown to inhibit the effect of 
epibatidine, demonstrating the antagonist effect of the partial agonist. Pre-
application of TC-2559 at the EC50 concentration of 1 µM was also found to 
inhibit the effect of nicotine (Fig. 7), at the concentration (1 µM) estimated to be 
maximal in the blood of smokers (Henningfield et al., 1997). Potent antagonist 
effects of partial agonists are, therefore, shown alongside their relatively 
enhanced agonist effects.  
 
Discussion  
Our experiments show that α4β2 partial agonists stimulate dopamine neuron 
firing via the activation of native α4β2* receptors and induce relatively enhanced 
maximal effects which are equivalent to full agonists and nicotine. The enhanced 
effect is predominantly attributed to the presence of receptor reserve, as 
efficacious α4β2 agonists, but not partial agonists, induced depolarisation block 
of firing in addition to the maximum firing increase via the activation of receptors 
in reserve. The maximum firing increase may, therefore, be induced by partial 
activation of the receptor pool. Consequently, partial agonists elicit maximum 
firing increase by activating all receptors without reserve or depolarisation block. 
The existence of native receptor reserve is, therefore, likely to affect the 
physiological effects of α4β2 partial agonists. 
 
α4β2 agonist-induced firing rate increase  
Nicotine and nicotinic agonists activate nAChRs on dopamine neurons to induce 
inward currents and membrane depolarisation (Calabresi et al., 1989; 
Pidoplichko et al., 1997; Klink et al., 2001), resulting in increased spontaneous 
firing rate (Picciotto et al., 1998; Yin & French, 2000; Chen et al., 2003; de Filippi 
 10
et al., 2010). However, bath application of agonists induced only narrow “window” 
currents on recombinant α4β2 receptors (Rollema et al., 2010; Papke et al., 2011) 
and native α3β4* receptors (Lester, 2004) due to profound desensitisation of 
receptors by agonists at both low and high concentrations. The therapeutic 
delivery of α4β2 partial agonists  may thus not be able to cause any significant 
agonist effects. However, we confirmed here that bath application of nicotine and 
α4β2 agonists activate α4β2* receptors and persistently stimulate dopamine 
neuron firing (Fig. 2) across a wide range of concentrations (Fig. 1), in contrast to 
the narrow “window” current on recombinant α4β2 receptors. The results may, 
therefore, indicate reduced, agonist-induced receptor desensitisation on 
dopamine neurons. Native receptor subtypes and associated proteins (Araud et 
al., 2010) in dopamine neurons may contribute to the effect. 
 Both α4β2* (* may denote α5, α6 or both) and α7 subtypes are 
functional receptors on dopamine neurons (Pidoplichko et al., 1997; Picciotto et 
al., 1998; Klink et al., 2001; Champtiaux et al., 2003). However, neither α6* nor 
α7 receptors were activated by α4β2-selective agonist TC-2559, nicotine, 
epibatidine or cytisine, indicating the predominant effect of (non-α6/α7)α4β2* 
receptors. In agreement with these findings, α6* nAChRs were shown to be 
predominantly expressed in the terminal regions of dopamine neurons 
(Champtiaux et al., 2003) and α7 receptors in less than half of the dopamine 
neurons (Pidoplichko et al., 1997; Klink et al., 2001). In addition, native α4β2* 
receptor currents in dopamine neurons are relative slow and longer-lasting 
(Pidoplichko et al., 1997; Klink et al., 2001), which may, therefore, underlie the 
persistent firing increase induced by bath-application of agonists. More 
interestingly, the incorporation of α5 subunits with α4 and β2 increased the 
“window” current in oocytes (Papke et al., 2011), suggesting that native α4β2α5 
receptors in dopamine neurons (Klink et al., 2001; Champtiaux et al., 2003) could 
also contribute to agonist-induced, persistent effects. Specific associated 
proteins that modulate desensitisation of native α4β2* receptors in dopamine 
neurons are currently unknown. 
 
Enhanced relative maximal effects of α4β2 partial agonists  
 More importantly, this study revealed enhanced relative maximal 
effects of α4β2 partial agonists on neuronal firing. Our systematic analyses of 
concentration-dependent effects of six partial and full α4β2 agonists on 
dopamine neuron firing show that all partial agonists induced larger maximal 
effects relative to full agonists. Most significantly, the 33% agonist TC-2559 
elicited similar maximal firing rate enhancement to nicotine and full agonists, and 
the 21% agonist cytisine induced 46% of the maximum firing increase (Table 1 
and Fig. 1A).  
 α4β2 agonists increase the firing rate by depolarising the membrane 
potential upon receptor activation. When full agonists at high concentrations 
induced additional depolarisation block of firing following the maximum firing 
increase (Fig. 3), larger membrane depolarisation that inactivates sodium 
channels was highly likely induced by further activation of receptors. As the 
α4β2* receptor subtype were shown to be predominantly activated by the 
agonists (Fig. 2) and partial and full agonists share the same α4β2* receptor pool 
(Fig. 4), full agonists, therefore, caused the maximum firing increase by activating 
only a proportion of the receptor pool, and depolarisation block by activating the 
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rest of the receptors in “reserve” at high concentrations. Partial activation of 
receptors on dopamine neurons is, therefore, sufficient for the maximum firing 
increase and a receptor reserve exists for this function. As the less efficacious 
agonists on recombinant α4β2 receptors induced less frequent depolarisation 
block (Fig. 3C), partial agonists may only weakly activate the native α4β2* 
receptors. Partial agonists on recombinant α4β2 receptors could, therefore, still 
be partial on native rodent receptors. However, by activating all receptors 
available without leaving any reserve, partial agonists may induce the equivalent 
partial receptor activation and cause the same maximum effect as full agonists. 
The experimental results are, therefore, in support of the existence of receptor 
reserve.  
 The existence of receptor reserve can enhance the relative maximal 
effects of partial agonist, and the size of the reserve can further determine which 
partial agonist to become maximally effective. On dopamine neuron firing, the 
size of the reserve was large so that the 33% agonist TC-2559 was fully effective, 
while the 21% partial agonist cytisine was submaximal. On dopamine release 
from striatal slices, however, both cytisine and TC-2559 exerted submaximal 
effects compared to nicotine and epibatidine (Smith et al., 2007), indicating a 
smaller or lack of receptor reserve there. The lower density of α4β2* receptor 
expression in the striatum (Marks et al., 1983) may be responsible for the smaller 
receptor pool and receptor reserve. 
 Does the existence of receptor reserve affect behavioural effects of 
partial agonists? It is interesting to note that cytisine and TC-2559 were partially 
and fully generalised to a nicotine cue in a drug discrimination paradigm, 
respectively (Smith et al., 2007), suggesting that the behavioural responses may 
be translated from their respective submaximal and maximal effects on dopamine 
neuron firing. Increased dopamine neuron firing is associated with increased 
dopamine release from terminals, resulting in greater reward potential. Although 
efficacious agonists are also effective at stimulating firing increase,  high 
concentrations may also induce depolarisation block of firing, reduce the release 
of dopamine in the brain and cause adverse behavioural effects. Indeed, while an 
optimal dose is often observed in nicotine self-administration (Picciotto, 1995; 
Pons et al., 2008), where the firing rate of dopamine neurons may be optimised 
for reward, high doses of nicotine cause tonic-clonic seizures in rodents (Salas et 
al., 2003), possibly due to excessive membrane depolarisation. Efficacious 
agonists may also excessively stimulate human nicotinic receptors, as smokers 
are also known to self-regulate nicotine intake to maximize the desirable effects 
(Benowitz & Jacob, 1985; Kassel et al., 2007). Conversely, partial agonists may 
also behave predominantly like an antagonist when acting on a nicotinic function 
without receptor reserve. On the treatment of anxiety, for example, cytisine 
behaved like an antagonist with negligible agonist effect (Picciotto et al., 2008). 
Behavioural effects of nicotinic partial agonists are, therefore, determined by their 
physiological effects, which are modulated by the existence of receptor reserve. 
 
Nicotinic partial agonists as smoking cessation aids 
 The therapeutic efficacy of a drug stems from the translation of its 
pharmacological properties on receptors to physiological effects. The 
translational processes for a receptor agonist are complicated as the balance 
between receptor activation and desensitisation depends not only on agonist 
concentration but also the speed and duration of delivery at target receptors. Our 
Formatted: English (U.K.)
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findings show that therapeutic delivery of α4β2 partial agonists may be able to 
activate native α4β2* receptors on neurons, because bath-applied agonists 
induced persistent dopamine neuron firing rate increase and prevented effects of 
nicotine. α4β2 partial agonists can, therefore, both mimic and compete against 
nicotine to preclude its rewarding effects, in support for the dual mechanisms for 
smoking cessation.  
 However, our results further show that partial agonists can become 
fully effective on neuronal function because of an existence of receptor reserve. 
For example, on the nicotinic stimulation of dopamine neuron firing, the 33% 
α4β2 partial agonist TC-2559 is fully effective. Therefore, to achieve partial 
activity for therapeutic purposes, the relative efficacies of agonists may need to 
be optimised taking into account of native receptor availability. We now know that 
on dopamine neuron firing, only partial agonists with relative maximum effects 
lower than 33% on recombinant human α4β2 receptors, such as cytisine, may 
elicit partial activity. This is in agreement with cytisine and its derivative, 
varenicline, being used currently as smoking cessation aids, although it is 
unknown to what extent receptor reserve may exist in smokers’ brain. The results 
from rodent brain may raise the issue that the interpretation of clinical efficacies 
of different α4β2 partial agonists requires taking into account of receptor reserve. 
  
 In conclusion, this study demonstrated that nicotinic α4β2 partial 
agonists are more effective at neuronal functions where there is receptor reserve. 
The size of receptor reserve at targeted neuronal functions may influence the 
physiological effects and clinical efficacies of partial agonists. 
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Figure legends 
 
Figure 1. Agonists for α4β2 nAChRs induced concentration-dependent 
firing rate increase in dopamine neurons. A. Nicotine (Nic)-induced 
concentration-dependent increase of the spontaneous firing rate. Rate histogram 
is plotted in 10s bins. Increases in firing rate by different concentrations of 
nicotine are shown. The increase induced by 10 µM nicotine (*) was followed by 
a period of firing cessation (#). B. α4β2-selective agonists TC-2559 (TC), 5-i-
A85380 (5-I-A) and ABT-594 (ABT), and non-selective agonists, epibatidine (Epi), 
nicotine (Nic) and cytisine (Cyt), all induced firing increase with increasing 
concentrations. Concentration-response curves were fitted with the Hill equation 
(the Hill slope was fixed at 1) and EC50 and Emax values for each agonist were 
obtained and shown in Table 1. Mean % firing rate increases (n ≥ 4 for each data 
point) were obtained for each agonist at the indicated concentrations. Error bars 
are shown at the negative direction only for clarity. C. The mean maximal 
increases of firing frequency (Hz) induced by top concentrations of each agonist 
are compared and the effect of Cyt was significantly smaller compared to the 
other agonists (* P < 0.05, one-way ANOVA followed by Tukey-Kramer multiple 
comparisons). D.The Emax of α4β2 partial agonists are relatively enhanced on 
neuronal firing as the data points for Cyt, TC and 5-i-A are located above the 
diagonal line (dashed). The Emax values for Epi, ABT, 5-i-A, Nic and TC are not 
different from each other and their mean is shown as the dotted line. The Emax 
value for Cyt is significantly lower than the other agonists (* p < 0.05, one-way 
ANOVA with Dunn’s pair-wise comparisons). E. EC50 values of agonists on 
neuronal firing and on recombinant α4β2 nAChRs are linearly correlated (slope = 
1, and the regression line passes the origin), indicating the similar rank order of 
potencies for agonists on both functions. Cyt is omitted from the plot because its 
EC50 value for recombinant α4β2 nAChRs was not obtained. The other agonists 
are plotted using the same colored symbols as in D. 
 
Figure 2. Inhibitory effects of nicotinic antagonists on agonist-induced 
increase in firing rate in dopamine neurons. A. Bath applications of α4β2 
partial agonists cytisine (Cyt, 10 µM ), nicotine (Nic,1 µM), and epibatidine (Epi, 
0.1 µM), significantly and persistently increased dopamine neuron firing 
frequency in rat VTA slices. Application periods are indicated by horizontal bars. 
Agonist-induced effects were inhibited by nicotinic antagonists mecamylamine 
(Mec 10 µM) and DHβE (2 µM) as indicated. The firing frequency was calculated 
from 10s bins. B. Effects of antagonists were compared. Agonist-induced effects 
were inhibited by Mec (10 µM) or DHβE (2 µM), but not by the α3/6 antagonist α-
conotoxin MII (CTX MII, 100nM), α7 antagonist methyllycaconitine (MLA, 10nM), 
or the ionotropic glutamate receptor antagonists CNQX (20 µM) or D-AP5 (50 
µM), indicating the predominant involvement of somatodendritic α4β2* nAChRs. 
Data are presented as mean ± SEM (n = 3-6) for each antagonist. 
 
Figure 3. Agonist-induced firing rate cessation in dopamine neurons. A and 
B, Epibatidine (Epi, 1 µM) induced an initial firing rate increase and subsequent 
firing cessation. Spike waveforms before (1), during (2) and after (3) Epi are 
compared in the inset. The reduced spike amplitude during firing rate increase (2) 
indicates significant underlying membrane depolarisation. Washing-out of Epi 
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allowed rapid recovery from firing blockade and reduced spike amplitude. 
Application of nicotinic antagonist DHβE reduced the firing rate to the baseline 
level, indicating residual receptor activation. C. % of neurons undergone agonist-
induced depolarisation block of firing is plotted against the Emax values of 
agonists on recombinant α4β2 nAChRs. A statistically significant correlation (r = 
0.99, slope = 1.1, P < 0.05) is found between the effects, showing that the more 
effective agonists on α4β2 nAChRs are more likely to induce depolarisation block. 
Abbreviations: Epi for epibatidine; ABT, ABT-594; 5-i-A, 5-I-A85380; Nic, nicotine; 
TC, TC-2559 and Cyt, cytisine. 
 
Figure 4.The stimulatory effects of epibatidine are inhibited by TC-2559. 
A and B. Both increase and cessation of firing rate induced by epibatidine (Epi 1 
µM) are inhibited by the pre-application of 10 µM TC-2559 (TC 10 µM) (TC+Epi 
in B, n = 3, * P < 0.05, NS P > 0.05, one-way ANOVA with Dunn’s pair-wise 
comparisons).  
 
Figure 5. Reduced effects of agonists on GABAergic neurons. 
A. Epi at 1 µM did not affect the firing rate or the spike amplitude (inset) of 
GABAergic neurons. B. Firing rate changes induced by Epi (1 µM) and TC-2559 
(TC, 1 and 100 µM) on GABAergic neurons (bar plot) are significantly smaller 
than on dopamine neurons (scatter plot, ** P < 0.01 compared to that bar plot, 
one-way ANOVA with Dunn’s pair-wise comparisons).  
 
Figure 6. Correlation between the effects of TC-2559 and cytisine in 
individual dopamine neurons. Effects of 1 µM TC-2559 (TC) and 10 µM 
cytisine (Cyt) were compared in the same neuron (A) and statistically significant 
correlation between the effects is shown (B. slope = 1 and the regression line 
passes the origin, **p < 0.01, n = 10), demonstrating larger effects of TC in 
neurons having larger responses to Cyt, which represent the relative size of the 
receptor pool in each neuron. Two consecutive applications of TC-2559 (1 µM) 
(1st TC and 2nd TC, n = 7) show repeatable responses (C and D), so that TC is 
less likely to have residual effects on subsequent Cyt. N.S. denotes no statistical 
significance (p > 0.05). Agonists are applied for 6 min as shown by the horizontal 
bars.  
 
Figure 7. The antagonist effect of partial agonist. Prolonged applications of 
TC-2559 (TC, 1 µM) induced persistent increase of firing rate (A and B, * p < 
0.05, one-way ANOVA with Dunn’s pair-wise comparisons) and inhibited effects 
of nicotine (Nic 1 µM, A and B, P > 0.05, n = 4, N.S. denotes no statistical 
significance), demonstrating the antagonist effect by receptor occupation.  
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